GSWM
SPRY icon

Golden State Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Golden State Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.89K Hold
484
– – ﹤0.01% 1255
2025
Q4 		$5.64K Hold
484
– – ﹤0.01% 1222
2025
Q3 		$4.86K Buy
+484
New +$6.95K ﹤0.01% 1257

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Golden State Wealth Management's SPRY Position: Q1 2026 in Review

Golden State Wealth Management held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 484 shares worth $3.89K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Golden State Wealth Management first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.64K in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Golden State Wealth Management held 484 shares of ARS Pharmaceuticals worth $3.89K as of Q1 2026.
  • Golden State Wealth Management left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Golden State Wealth Management's portfolio in Q1 2026, its #1255 holding.
  • Golden State Wealth Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Golden State Wealth Management's ARS Pharmaceuticals position peaked at $5.64K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.